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Abstract
Background: Cystic fibrosis (CF) is a life-limiting genetic condition in which daily therapies to maintain lung health
are critical, yet treatment adherence is low. Previous interventions to increase adherence have been largely
unsuccessful and this is likely due to a lack of focus on behavioural evidence and theory alongside input from
people with CF. This intervention is based on a digital platform that collects and displays objective nebuliser
adherence data. The purpose of this paper is to identify the specific components of an intervention to increase and
maintain adherence to nebuliser treatments in adults with CF with a focus on reducing effort and treatment
burden.
Methods: Intervention development was informed by the Behaviour Change Wheel (BCW) and person-based
approach (PBA). A multidisciplinary team conducted qualitative research to inform a needs analysis, selected, and
refined intervention components and methods of delivery, mapped adherence-related barriers and facilitators,
associated intervention functions and behaviour change techniques, and utilised iterative feedback to develop and
refine content and processes.
Results: Results indicated that people with CF need to understand their treatment, be able to monitor adherence,
have treatment goals and feedback and confidence in their ability to adhere, have a treatment plan to develop
habits for treatment, and be able to solve problems around treatment adherence. Behaviour change techniques
were selected to address each of these needs and were incorporated into the digital intervention developed
iteratively, alongside a manual and training for health professionals. Feedback from people with CF and clinicians
helped to refine the intervention which could be tailored to individual patient needs.
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Conclusions: The intervention development process is underpinned by a strong theoretical framework and evidence
base and was developed by a multidisciplinary team with a range of skills and expertise integrated with substantial
input from patients and clinicians. This multifaceted development strategy has ensured that the intervention is usable
and acceptable to people with CF and clinicians, providing the best chance of success in supporting people with CF
with different needs to increase and maintain their adherence. The intervention is being tested in a randomised
controlled trial across 19 UK sites.
Keywords: Cystic fibrosis, Adherence, Intervention development, Behaviour change wheel, Person-based approach,
Digital intervention, Habit formation
Key messages regarding feasibility
 In order to develop an intervention to increase
adherence to treatment in people with cystic fibrosis
(CF), we needed to develop an intervention using
behavioural science theory and evidence and
informed by people from our target population.
 We developed and refined a complex intervention
underpinned by a strong theoretical framework and
evidence base. The CFHealthHub intervention is
usable and acceptable to people with CF, providing
support for people with CF with different needs to
increase and maintain their adherence.
 We have a digital platform, intervention manual,
and training package for use in the main trial of the
CFHealthHub intervention
Background
Cystic fibrosis (CF) is an inherited genetic condition that
affects approximately 10,500 people in the UK and 100,
000 worldwide [1]. The condition causes the build-up of
thick sticky mucus in the digestive system and lungs
which can result in recurrent lung infections, progressive
lung damage, and respiratory failure [2]. People with CF
require a time-consuming regimen of treatment in order
to maintain their health [3, 4].
There are effective inhaled treatments for CF, usually
delivered via a nebuliser, that include antibiotics to re-
duce infections and mucolytics to thin mucus and to
keep airways clear. However, consistent with other long-
term conditions, adherence to nebuliser treatments is
low [5–7]. Low adherence is associated with increased
lung damage and additional need for treatment with
intravenous (IV) antibiotics, with higher associated treat-
ment costs [6, 8–11], and significant impacts on quality
of life [12]. There is a need for effective interventions to
increase adherence to treatment in this population.
Interventions have so far shown limited success in in-
creasing adherence in people with CF [13–15]. There
are a number of potential reasons for this. First, the in-
terventions may not be targeting the most appropriate
factors [16]. Second, there is a lack of studies using a
theory and evidence-based approach [17]. Third, inter-
ventions may assume that one-size fits all despite evi-
dence that the factors affecting adherence may be
person-specific [18]. Even where there have been re-
ported successes, adherence outcomes have not been
measured objectively and therefore the findings may not
be reliable. Adherence is often measured by either self-
report or medicine possession ratio (MPR). In the UK,
objective estimates of median adherence are in the re-
gion of 36% [5], whereas MPR for inhaled therapy are in
the region of 65% [11] and self-report around 80% [5,
11]. To be sure of success, we need to be able to assess
the impact of an intervention on sensitive, objectively
measured adherence.
With the advent of nebuliser devices (eTrack™, Pari
and I-neb™, Phillips Respironics) that record time and
date stamped treatments and support data transfer, we
now have a means to capture objective treatment adher-
ence data. This is important not only as an outcome
measure for any intervention, but also to inform patients
and clinicians of current adherence, given evidence of
the effectiveness of feedback in order to change adher-
ence behaviour [19, 20]. A key aim of the research
programme was to develop a digital platform that could
capture and display objectively measured nebuliser ad-
herence and ‘make adherence visible’ and then to de-
velop an associated behaviour change intervention to
promote and support increases in adherence and the
maintenance of adherence in the longer term. This
paper describes the process of the development of the
CFHealthHub digital platform and the associated behav-
iour change intervention to support adherence to nebu-
lised treatment in adults with CF.
Intervention development approach
The approach to intervention development that we
employed was the combined approach identified in a
taxonomy of intervention development; a ‘theory and
evidence-based approach’ with a ‘target population-
based’ approach [21]. The Behaviour Change Wheel
(BCW) [22, 23] is a theory and evidence-based approach
[20] selected because of the need to change the
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behaviour of people with CF. The person-based ap-
proach (PBA) to intervention development [24] is a tar-
get population-based approach [21] in which feedback
from the target population is collected. It is complemen-
tary to BCW [24] and has been previously used along-
side the BCW [25].
The BCW was devised following a systematic evaluation
and synthesis of 19 frameworks of behaviour change and
considers Capability, Opportunity, and Motivation in relation
to Behaviour (COM-B model) [22]. The approach follows
three stages: (i) Understanding the behaviour, identifying
clear and specific target behaviours, and analysing the factors
that impact on that behaviour and the need for change. This
stage often uses the complementary Theoretical Domains
Framework (TDF) [26, 27] that specifies 14 key domains
from 33 behaviour change theories, that each influence cap-
ability, opportunity, or motivation [22, 28]. (ii) Identifying
intervention functions and policy categories, i.e. ways to en-
act interventions, to achieve behaviour change, and (iii) iden-
tifying specific behaviour change techniques (BCTs), i.e. the
specific active ingredients to change behaviour as described
in the behaviour change technique taxonomy [29], and
modes of delivery. The approach incorporates a systematic
assessment of the available options and choices and has been
widely used in the development of behaviour change inter-
ventions in settings including adherence (e.g. [30, 31]).
The PBA was devised from experience of developing
digital interventions and utilises mixed methods with people
from the target population to inform all stages of the inter-
vention development in an iterative process. Given that we
started with a plan to include a digital platform to display ad-
herence data, PBA was an appropriate approach to the devel-
opment of this digital intervention.
Conceptual framework and aims of the intervention
We started this intervention development process with
some initial ideas about what the intervention might in-
clude and the kinds of resources we might have to deliver
it. Early work by the team using quality improvement and
process mapping [32] had highlighted the need for object-
ive data on medication adherence in CF, and we explored
how this could positively impact on clinical practice [33–
35]. Therefore, we aimed to develop a digital platform that
could capture and display objective nebuliser adherence
data to patients and clinicians. We understood the import-
ant role that the clinical teams play in CF and that adher-
ence support and therefore intervention delivery would be
supported by a trained healthcare professional [34].
Early work by members of the team [36, 37] had also
considered barriers to adherence in CF and this fed into
a conceptual framework of the broad factors influencing
adherence and how an intervention might act on these
factors to produce and then maintain change. A particu-
lar focus of this early work was a consideration of how
adherence could be maintained without increasing per-
ceived effort or burden. This conceptual framework
drew on the COM-B model and also on other models
of adherence and behaviour change and is presented
in Fig. 1 (and see [22] p. 81).
The conceptual framework proposes that adherence be-
haviour is influenced by reflective motivation, i.e. a rational
weighing up of the perceived necessity against the perceived
concerns about treatment [38]. For some people, an inter-
vention would need to address motivation before any other
strategies could be successful since without this people with
CF would not start to initiate attempts to adhere to treat-
ment. Those who want to increase adherence to treatment
will make attempts to do so but in many cases these at-
tempts will be hindered by a range of capability and oppor-
tunity barriers. An intervention needs to support people to
overcome these barriers so that they can adhere to their
treatment. Self-regulation is one way in which people can
sustain the life-long adherence to preventative inhaled treat-
ment required to maintain lung health. However, there is evi-
dence that self-regulation is difficult to maintain [39] and
requires effortful self-control [40] and self-regulatory capacity
[41]. Habit theory [42] proposes that habits formed through
regular repetition of a specific behaviour in response to a cue
over time (initially maintained through self-regulation) comes
to trigger the behaviour (automatic motivation) such that
habit strength then predicts the likelihood of the behaviour
and motivation-driven self-regulation becomes less import-
ant. Habits have been proposed to be one of the key mecha-
nisms by which behaviour change can be maintained in the
longer term [43] with less perceived effort and burden, and
thus a key aim of the intervention is to promote habit
formation.
Having a conceptual framework from the start of the
project provided a structure that guided intervention de-
velopment. We recognised the potentially important role
of capability, opportunity, and motivation and the overall
aim of the intervention. However, we needed to under-
stand the specific barriers and facilitators to adherence
for people with CF and how we could best develop an
intervention within this conceptual framework that
would enable people to adhere and make habits.
Methods
The team
The core intervention development team included
people with different perspectives, skills, and expertise:
MA is a health psychologist with expertise in the devel-
opment of theory-based behaviour change interventions.
PW is a computer scientist and health informatician
with expertise in the design and development of digital
health platforms. SD and AOC are health services re-
searchers with experience in undertaking qualitative re-
search with behaviour change interventions. MH and JB
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Fig. 1 Conceptual framework for sustained adherence to treatment
Fig. 2 Process of intervention development
Arden et al. Pilot and Feasibility Studies             (2021) 7:1 Page 4 of 18
are research physiotherapists with expertise in respira-
tory health and supporting patients with CF with their
adherence. MW is a consultant in respiratory medicine
working with adults with CF and with expertise in qual-
ity improvement. DB has cystic fibrosis and is a health
services researcher and co-ordinated the patient and
public involvement (PPI) group.
Dynamic and iterative approach
Intervention development is not a simple linear process. Dif-
ferent methods and actions are taken at different stages but
they are used in a dynamic way in that they overlap and are
revisited throughout the process [44]. The team followed an
intervention development process with stages that fed into
each other as illustrated in Fig. 2. Software development used
the Agile process [45]. This involved the continuous delivery
of working software to meet the shifting requirements identi-
fied by the intervention development team. The process re-
quired close collaboration between the technical and
intervention development teams.
Ethical approval was gained for all studies [REC refer-
ences: 15/YH/0332; 15/WS/0089] and all participants
gave written informed consent.
Stages of development
There are seven identified domains of actions taken
across different approaches to intervention development:
conception, planning, designing, creating, refining, docu-
menting, and planning for future evaluation [21].
Stage 1: Planning
Understanding practicalities of delivery
Input from members of the team working in the NHS
context enabled us to understand that the intervention
would need to be delivered flexibly by different members
of the multidisciplinary team (MDT) or by health profes-
sionals recruited from outside of the MDT, due to NHS
shortages in staff [46]. Thus, the intervention that was
developed needed to be able to be delivered by a range
of health professionals in order to ensure that future im-
plementation was feasible.
Understanding the behaviour
We undertook a needs analysis for the intervention in-
formed by the following.
Literature review We reviewed the literature to identify
key barriers to nebuliser adherence in adults with CF.
This included a systematic review of qualitative studies
[47], and we updated our knowledge with key papers
published during the course of the development phase
(e.g. [48]).
Qualitative research with patients We conducted semi-
structured interviews with 18 adults with cystic fibrosis from a
single CF centre in the UK sampled by objective adherence,
gender, age, and deprivation index. The data-prompted inter-
views [49] included the presentation of a graph showing each
person their nebuliser adherence data over the last 6months.
The topic guide was informed by the literature review and
based around understanding adherence in the context of cystic
fibrosis and life in general, and the COM-B model [22] and
TDF [26]. The data from these interviews were analysed using
two different approaches; a framework analysis using the TDF,
including a comparison of factors identified by higher and
lower adherence [50], and a discursive analysis [51].
Survey with health professionals We consulted health
professionals to understand their perceptions of the bar-
riers to adherence and possible solutions to address
those barriers. Fourteen clinicians working at five adult
CF centres across the UK were sent an email survey
which was completed and returned by six clinicians.
PPI Findings and interpretation of the interviews were
provided to the patient co-applicant who led the PPI
group to ensure that they were plausible and realistic.
DB was involved from a very early stage in discussions
around the proposed intervention, including the ration-
ale for its use, as well as the design and functionality of
the proposed website.
Stage 2: Designing and creating the prototype
intervention
Stage two of the intervention development process in-
volved the development of a prototype intervention.
There were two parts to the CFHealthHub intervention:
(i) the digital platform displaying adherence data and on-
line content and tools and (ii) the interventionist-
delivered aspects of the intervention delivered during
contact with a health professional. Frequent meetings of
the intervention development team, informed by parallel
discussions of the patient and public involvement group,
were held during stages 2 and 3. At these meetings, we
discussed input from each of the following activities.
Design of the prototype intervention using the Behaviour
Change Wheel approach
Following the Behaviour Change Wheel approach1, we
mapped intervention functions and behaviour change
techniques to the identified needs of the intervention.
Options were considered and discussed during meetings
of the intervention development team, and decisions
1We omitted the selection of policy categories stage of the BCW
process as the decision to focus on service provision had been made
previously during the development of the programme aims.
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were informed by the APEASE criteria [23]: affordability
refers to the cost of the intervention, which must be
within budget; practicability refers to the extent to which
the intervention can be delivered as designed to the tar-
get population; effectiveness/cost-effectiveness refers to
effectiveness of the intervention in a real-world context
in relation to that which is most cost-effective; accept-
ability refers to the extent to which the intervention is
judged to be appropriate by different stakeholders; side-
effects/safety includes unintended consequences of the
intervention; and equity refers to the extent to which the
intervention impacts on disparities in living standards,
health, and wellbeing. We also considered the mode of
delivery of each of the behaviour change techniques,
whether they were delivered via the digital platform or
whether they were delivered by a health professional
acting as an interventionist. MH, a physiotherapist expe-
rienced in the delivery of adherence support in CF care,
informed the development of the interventionist-
delivered components.
Design of the CFHealthHub digital platform
The first phase of technical development was to develop
the process and mechanisms by which inhalation data
(time-stamped nebulisations) could be automatically
captured from third party devices and software, trans-
ferred securely, and displayed in a usable way on a
digital platform in relation to prescription data (i.e. treat-
ment taken/treatment prescribed). The data transfer
flow is shown in Fig. 3. From the eTrack nebuliser, in-
halation data was automatically sent to a Qualcomm Life
2net Hub located in the participant’s home. Data was
transferred from the Qualcomm Hub to a secure server
maintained by Pari and then forwarded on to the
CFHealthHub server for display and use in the
CFHealthHub digital platform. Data transfer was in real-
time and required no additional actions by the partici-
pant over and above normal nebuliser usage, assuming
all devices maintained connectivity with the required
networks. This phase also involved a 6-week develop-
ment and testing phase, where the data transfer mechan-
ism was tested, and the data quality of the transmitted
data was validated (see Fig. 2, prototype intervention 1).
This was refined over a number of iterations. The need
for specific content and tools that arose from the inter-
vention development work fed into further technical
developments and prototype releases.
Stage 3: Iterative refinement of the prototype using the
person-based approach
Five participants were people with CF who were aged 16
or older, on the CF registry, provided with an eTrack
nebuliser and Qualcomm hub, and given access to the
CFHealthHub platform in order to assess the ability of
Fig. 3 Data transfer flow
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the system to successfully record and display nebulisa-
tions. They were followed up after 1 week to trouble-
shoot any data upload issues and interviewed after a
period of 1 month to give them time to use the proto-
type intervention.
Twenty-two participants were recruited into the itera-
tive development study. Participants were people with CF
who were aged 16 or older, on the CF registry, and willing
to take inhaled mucolytics via a chipped nebuliser
(eTrack). They were provided with an eTrack nebuliser
and Qualcomm hub. They received four sessions of inter-
vention delivery from a physiotherapist and were given in-
dependent access to the CFHealthHub web platform. We
conducted 18 semi-structured telephone interviews with
participants in different cycles of the software develop-
ment (see Fig. 2, protoypes 1–5) to ask about acceptability
of the appearance and functionality of the digital platform
and potential improvements. Additionally, we conducted
six in-depth think aloud interviews [52, 53] with partici-
pants whilst they were using a version of the CFHealth-
Hub website. The screen and audio of the interview was
recorded using Camtasia™ software. This allowed the soft-
ware team to identify technical and navigational issues
with the website that were corrected in subsequent re-
leases. We also interviewed the physiotherapist delivering
the intervention at two time points for wider views about
how to deliver the intervention to patients and how that
linked to the clinician view of the website.
PPI
Input was provided by DB and wider PPI reference
group throughout the early development phase of the
intervention. Initially, this involved providing input into
the proposed content for the textual parts of the website,
in terms of the type and level of information that was
felt appropriate, not only for people with CF, but others
involved in their care.
As the digital platform was developed, PPI input was
again provided at regular intervals. Members of the PPI
reference group were given the opportunity, on a num-
ber of separate occasions, to explore iterations of the
website through a demonstration version of the website.
Feedback was then provided in meetings of the group,
which was then passed back to the wider study team.
Aside from input on the design, group members also
provided comment on practical issues around data shar-
ing within the website, and the user guide that had been
produced to accompany it.
Stage 4: Documenting the intervention
At the end of this process, in readiness for the pilot trial,
we created an intervention manual that outlined the key
components of the intervention, how to use the CFHealth-
Hub digital platform, and the manner and structure of
delivery, and an associated training programme for inter-
ventionists as well as a user guide for participants.
Stage 5: Further refinement of the intervention following
piloting
Whilst descriptions of the intervention development
process often stop before piloting and feasibility testing
[44, 54], we utilised the pilot and feasibility study [55] to
identify further refinements that were made to the inter-
vention before it was used in the final randomised con-
trolled trial.
The pilot and feasibility study consisted of a mixed
methods process evaluation undertaken concurrently
with a pilot RCT in two UK CF centres. Participants
were people with CF who were aged 16 or older, on the
CF registry, and willing to take inhaled mucolytics and/
or antibiotics via an eTrack nebuliser. Three interven-
tionists were trained to deliver the intervention in six
face-to-face meetings over 5 months to 32 participants
who had access to the CFHealthHub (CFHH) website
throughout. We conducted 25 semi-structured face-to-
face interviews with patients in the intervention arm of
the RCT (n = 14), interventionists delivering the inter-
vention (n = 3 at 2 time points), and members of the
wider multidisciplinary team (MDT) (n = 5).
The findings from the quantitative [55] and qualitative
[56] aspects of the study were triangulated [57] and the
implications for the further refinement of the interven-
tion discussed by the development team with input from
PPI representatives. As the software was more mature at
this stage, changes became more costly in terms of im-
plementation effort and therefore regular prioritisation
meetings were conducted where the team agreed on
which requirements would be implemented. Decisions
about which work to prioritise were made using the
MoSCoW criteria of prioritisation: Must have, Should
have, Could have, and Won’t have [58].
A full description of the intervention was written fol-
lowing the TiDieR (Template for Intervention Descrip-
tion and Replication) checklist [59].
Results
Stage 1: Planning the intervention
The research confirmed that different factors influenced dif-
ferent people’s ability to adhere and it was therefore import-
ant, for reasons of equity, to develop an intervention that
addressed multiple capability, opportunity, and motivation
barriers to adherence. Our behavioural needs analysis en-
abled us to identify the factors that the intervention needed
to address (see Table 1) and the team considered and dis-
cussed whether the intervention should be designed to ad-
dress each of these needs. Three domains were excluded at
this stage (see Table 1 for rationale).
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Stage 2: Designing and creating the intervention
The stage 1 analysis indicated that a number of needs
were replicated across different TDF domains (e.g. need
to address treatment concerns), and the intervention de-
velopment team therefore generated ‘themes of need’ for
the intervention (see Table 2). The selection of interven-
tion functions matched to each theme of needs is de-
scribed in Table 2 along with the reasons for inclusion/
exclusion according to the APEASE criteria. Table 2 also
displays the selection of behaviour change techniques
(BCTs) to match the needs and intervention functions
selected. BCTs that were considered but rejected by the
team according to the APEASE criteria are also shown.
Discussions about the intervention considered the
needs of different types of patients with different barriers
to adherence, as indicated in the analysis of the stage 1
qualitative work. We therefore considered how the inter-
vention could be tailored to meet the needs of individ-
uals and to reduce the possibility of overwhelming an
individual with lots of BCTs that might not be useful or
Table 1 Needs analysis by COM-B and TDF with decisions for inclusion/exclusion in the intervention
COM-B
component
TDF domain Needs analysis Inclusion/exclusion
Physical
capability





Knowledge Need to know about the correct treatment-taking proce-
dures, to understand treatment action and the import-
ance of nebuliser treatment






Need to remember to take treatment Included
Behavioural
regulation
Need to develop routines, plans, and habits for treatment







Need to have a time, place, and the equipment do take
treatment
Need to develop strategies to take treatment around





Social influences Need positive support from family, healthcare
professionals, and/or others to do treatment







Need to develop a social identify that is consistent with
treatment adherence
Excluded—social identity change in the context of
adherence is not well understood
Beliefs about
capabilities
Need to develop confidence in the ability to take and
adhere to treatment
Need to develop strategies to take treatment at times or
in situations when it is more difficult
Included
Optimism Need to be optimistic that full treatment adherence is
possible




Need to believe that treatment is effective and necessary
for long-term health, symptom reduction, avoiding IVs/
hospital stays
Need to believe that treatment is important irrelevant of
perceptions of current wellness
Need to address treatment concerns
Included
Intentions Need to encourage intentions to adhere to treatment
and avoid periods of intentional non-adherence
Included
Goals Need goals for treatment adherence




Reinforcement Need to provide some reinforcement for treatment-taking
Need to address treatment concerns
Included
Emotion Need to focus on emotional drivers for adherence (fear,
anticipated regret)
Need to address low mood and avoidance
Excluded—not acceptable to focus on fear and may
increase avoidance. Addressing low mood/depression
outside the scope of this intervention (signposting to
other support services)
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Need to believe that
treatment is effective















on the importance of
treatment-taking even
when well, effectiveness















acceptable to patients or
health professionals to




















9.2 Pros and cons: Not
practical as would take








induce fear given life-
limiting nature of CF
(practical, side-effects,
equity).











a nebuliser, a hub, and a
digital platform to track














no easy mechanism to
monitor symptoms or
health and changes may
be due to factors other
than adherence (practical,
side-effects)















rewards when goals are
met)
Coercion—not
acceptable to patients or
health professionals to
focus on punishment for
not meeting goals
Modelling—not clear























outcome goals could be
impacted on by factors
outside of the individual’s
control and could result
in demotivation (side-
effects)
A need to have
confidence in the ability
to adhere to treatment
(beliefs about capability,
social opportunity)




ability to take and
adhere to treatment
Modelling (providing
role models of people
who have increased their







practical to change the
environmental barriers
that make treatments
feel difficult to do
Education—not likely to













could create social norms
for non-adherence given
low median levels (side-
effects)
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relevant. There were two key aspects of tailoring that we
incorporated early on: modules of content and paths
through the intervention. In relation to the need to
understand treatment, people had a range of necessity
and concern beliefs about the treatments that they had
been prescribed, and we only needed to address their
specific beliefs related to lower adherence. To address
this, we identified the need for a personalised area where
we could locate specific targeted and tailored content
which we named the Toolkit. Participants could access
their toolkit directly from the home page. Educational
and persuasive content was grouped into six themed
modules of content informed by the literature and our
qualitative work, e.g. Why is it important that I do my























positive self-efficacy) confidence likely to be
based on past
















digital tools on which to













contract would take too
much time (practical)
15.2 Mental rehearsal of
successful performance:
not likely to be effective
given that it is not
treatment taking that is
the challenge but
adherence in a range of
contexts (effective)



























others to do treatment
Need to develop
strategies to take
treatment at times or
in situations when it is
more difficult
Training (skills to be able











digital tools on which to










make plans about how
to overcome them or
reduce their effects)
Modelling (role models
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nebuliser treatments every day? and I have concerns
about my nebuliser treatments. We devised an algorithm
to automatically prioritise up to three modules of con-
tent for each participant based on their responses to
matched items in the BMQ-Specific2 [38]. For example,
a ‘strongly disagree’ response to the beliefs statement,
This nebuliser treatment protects me from becoming
worse, made it more likely that they would be matched
to the I’m not convinced that my nebuliser treatment
works module. Interventionists could override and
change modules if discussions with participants indi-
cated other or changed priorities over the course of
intervention delivery identified during review sessions.
Following consultations, interventionists could also se-
lect specific modules of problem-solving content and
videos matched to the specific needs of the participant
and place these in the Toolkit area.
The educational/persuasive content of the modules was
created to ensure that the information was accessible and
meaningful to people with different needs and different
perceptions of ‘credible sources’. It included simple ani-
mated videos of treatment action, patient stories and links
to external websites (e.g. CF Trust, NHS) and Cochrane
reviews about drug treatments. All of the content was
reviewed by the PPI groups and feedback was sought
throughout the iterative development process.
We understood that setting specific goals and plans
for treatment would only be effective if people were suf-
ficiently motivated to increase their adherence, and if
not, then the intervention should follow a different path
that replaced goal setting/planning with ensuring a need
to understand treatment and confidence building using
the modules and videos available on CFHealthHub and
open, non-judgmental discussions with patients.
Some aspects of the intervention were less about the
tools and content of the CFHH website and more about
how the interventionists interacted with participants. For
example, the self-efficacy intervention components
required that interventionists focused on times when
treatment had been taken rather than times of non-
adherence during discussions about treatment
graphs.
Stage 3: Refining the intervention
Feedback from discussions about the behaviour change
techniques and the iterative development study fed into
both the technical development of the CFHealthHub
digital platform and how the intervention would be deliv-
ered by health professionals (the interventionist-delivered
components). The versions of CFHealthHub that the par-
ticipants received changed over time as new content and
tools were added into the digital platform (see Table 3).
Table 4 provides the main feedback from participants and
interventionists from this process along with how these
were responded to in the development process.
Stage 4: Documenting the intervention
The final intervention was documented in a manual for
interventionists. This included the following sections
that focused on motivating health professionals about
the value of the intervention as well as the knowledge
and skills that they needed to deliver it:
 Description of the overall intervention and the
rationale for its development
 Orientation to the CFHealthHub digital platform
including the data displays, behaviour change
content and tools, and how to use them
Table 3 Key components of prototype CFHealthHub digital platform versions 1–5
Version Key components
1 Basic adherence display (blue) + basic prescription entry
2 First behaviour change intervention release: includes my treatment, problem solving, and my toolkit
Allows clinicians to add/edit patients
Basic patient analytics included (page clicks)
3 Action plan tool
Adherence display updates to show treatment times in labels
Enhanced analytics to capture graph views and clicks
4 Updated designs for my treatment (more lively colours and images)
24-hour clock used in labels on graphs for clarity about timing of treatments
5 Clinician report page added
Screening tool added to tailor my treatment
Coping plans added
Finalised revised design and content of my treatment
Revised design and content of problem solving
Revised design and content of my toolkit
2We also included an additional belief item identified as important in
our qualitative work: Nebulised antibiotic treatments are more
important for my health than IV antibiotics
Arden et al. Pilot and Feasibility Studies             (2021) 7:1 Page 11 of 18
 Plans for different types of intervention delivery
sessions including how to prepare for them
 Information about how to tailor the intervention to
suit different patients’ needs
 Intervention delivery using a person-centred
approach
An associated training programme for interventionists
was developed.
Stage 5: Further refinement following piloting
The outcomes of the pilot and feasibility study are described
in detail elsewhere [55, 56]. Key outcomes that fed into




Participants thought blue adherence graphs look and homepage
looked too ‘NHS’ and boring.
Accept Changed design to look more distinctly CFHealthHub. More images
Some participants liked the picture on the homepage, other did
not. There was no consensus about which image was preferable.
Some participants requested to personalise with their own images.
Accept Needs to feel like it belongs to the participant. There is no one
image that meets the needs of everyone. Images could be of a goal
(e.g. upcoming holiday) which could serve to act as a motivator
Participants wanted a forum or some way to interact with other
people with CF, to share experiences, problems, and ideas.
Reject Concern that this would require moderation (not practical) and that,
given that low adherence is very common, could serve to normalise
non-adherence and demotivate participants. Instead decided to in-
corporate ‘talking heads’ video clips—providing some information
from others with CF but where we could control the content.
Participants want to instantly see achievements/progress on graphs.
Suggested traffic light system. Wanted to see data over a longer
time frame.
Accept Some concern about traffic light system—specifically that too much
red would put people off. But suggestion came up frequently.
Modified over iterations so that green = hit target, amber = some
treatment but not met target, red date = not treatment taken.
Participants able to open out data to look over a longer period.
Participants confused by prescription entry. Suggested making this
clinician entered with mechanism by which participants can flag if
their prescription changes.
Accept Correct prescription data is vital to success of the intervention as
this is what the adherence data is based on. Important to get right.
Clinicians suggested that it would be useful to be able to see
treatment times easily, e.g. when you hover over a bar on the
charts.
Accept Clear benefit for both patients and clinicians.
Some participants go to bed late and their last treatment appears
on the following day’s graph. Would be useful to be able to modify
the time for the end of day to adjust this to meet different lifestyles
of patients
Reject Extensive programming task to change the basic time set up from
midnight-midnight day.




Limited engagement with CFHealthHub outside of visits
with the interventionist
Accept To address this, we prioritised the development of the CFF app for the trial
(must have) and we added tools to encourage engagement, i.e. push
notifications sent from the app each Monday congratulating participants on
meeting their target or encouraging them to start again. We also added a
reminder message sent if CFHH had not been accessed for a period of 2
weeks.
Fewer interventionist sessions were delivered than
anticipated
Accept We devised a clear intervention pathway that indicated the frequency,
interval, and pattern of intervention sessions for each participant for the
trial.
Limited delivery of some key BCTs by interventionists Accept Modify interventionist training and handbook and create worksheets to
follow. Monitor delivery of key BCTs during trial.
Changes to the target line changed the target line for all
time periods
Accept Keep and show historical target lines, and traffic light system in response to
the specific targets at a specific time-point.
Lack of faith in the validity of the adherence data by
participants and interventionists
Accept Some initial problems with the pairing of devices caused some issues with
data at the beginning of the pilot trial. High quality control to ensure
effective pairing. Some cases the data appeared correct. Created further
training and protocols on missing data and how interventionists should
response to scenarios in which the validity of data was questioned.
Some participants did not want to watch videos of other
people with CF. Making social comparisons was threatening.
Accept Inclusion of ‘talking heads’ videos made an optional part of the intervention.
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further development of the intervention and how they were
responded to in subsequent developments are described in
Table 5, and the final intervention that was used in the ran-
domised controlled trial are described in Table 6.
The intervention manual was revised to address the
identified need for change and to include information
about the CFHealthHub mobile apps (iOS and Android)
and associated functions. We developed worksheets for
interventionists to follow during delivery of the interven-
tion sessions. These worksheets included step by step in-
structions about how to interact with the CFHH content
and the participant and included hints about how to
phrase questions. An example worksheet for the first
intervention visit is included in supplementary files. The
associated training programme for interventionists was
revised to be delivered in 2 face-to-face training days
with 4 days of independent online training delivered via
a virtual learning environment and ongoing tutorial
support.
Modifications and adjustments to how the interven-
tion was tailored and personalised were also considered
and these are described in Tables 7 and 8.
Discussion
The CFHealthHub intervention which comprised a
digital platform and delivery by a health professional
Table 6 Final intervention BCTs and mode of delivery
Module BCTs Mode of delivery
My treatment 4.1 Instruction on how to perform
the behaviour
5.1 Information about health
consequences
9.1 Credible source
5.2 Salience of consequences





• Demonstration of techniques for nebuliser use, cleaning and treatment mixing
• Information about CF, the need for treatment, how each treatment works, and the importance
of adherence
• Information presented in a variety of ways though written text, patient stories, ‘talking heads’,
and animation videos, with links to external content including Cochrane reviews
• Range of different credible information sources including PWCF, Clinicians, links to scientific
papers
Interventionist:
• Interventionist introducing and highlighting relevant content on CFHealthHub
• Interventionist eliciting self-talk through discussion of motivation
Self-monitoring 2.2 Feedback on behaviour
2.3 Self-monitoring of behaviour
12.5 Adding objects to the
environment
CFHealthHub
• Charts and tables of objective adherence data presented within CFHealthHub
Interventionist
• Introducing and explaining charts and tables to participants
Confidence
building
6.1 Demonstration of behaviour
15.1 Verbal persuasion about
capability
15.3 Focus on past success
CFHealthHub
• ‘Talking heads’ videos of coping stories within CFHealthHub
Interventionist
• Interventionist encouraging focus on periods of higher adherence on charts
Goal setting
and review
1.1 Goal setting (behaviour)
2.2 Feedback on behaviour
1.6 Discrepancy between current
behaviour and goal




• Indication of goal line on charts of adherence
• Visual indication of goal met on CFHealthHub
• (Optional) Weekly push notifications indicating whether goal was met
• (Optional) Reward messages sent when goal met
Interventionist
• Discussion and agreement of goals with interventionist
• Review of goals
• Suggested steady increase in goal as improvements are made
• Feedback and social reward on progress




• Action planning tool and storage within CFHealthHub
Interventionist
• Help to focus on identifying consistent cues and linking to behaviour (habit formation)





12.1 Restructure the physical
environment
15.4 Self-talk
3.2 Social support (practical)
4.1 Instruction on how to perform
the behaviour




• Solution bank within CFHealthhub (including advice to problem solve, restructure the physical
environment, engage social support)
• Coping planning, day planner, and party planner tools and storage within CFHealthHub
• Videos demonstrating correct use of nebulisers within CFHealthHub
Interventionist
• Tailored problem-solving guided by interventionist
• Support to create day plans/party plans where appropriate
• Support to construct if-then coping plans including identifying self-talk where appropriate
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Table 7 Tailoring of the intervention components to meet specific participant needs
Tailored component How are non-tailored components accessed How version is determined
Contents of ‘My treatment’ and ‘Problem-solving’
focus on information relevant to current
prescription drugs.
All generic information in available to all
participants to browse. Information on
treatments not currently prescribed are
available but minimised.
Prescription is entered into CFHealthHub at
consent and altered whenever there is a
prescription change. CFHealthhub automatically
tailors content based on this information.
Modules of ‘My treatment’ are selected and
placed into ‘My Toolkit’ based on the scores on
the BMQ-Specific [38] questionnaire with one
additional itema.
Participants can browse all modules of ‘My
treatment’.
Participants’ responses to the BMQ questionnaire
[38] are entered into CFHealthHub at consent.
CFHealthHub recommends the most relevant
modules based on a scoring algorithm. If
CFHealthHub recommends more than three
modules then interventionists select three based
on the scores and their judgement based on
conversations with the participant. Modules can
be changed throughout the intervention and
these are recorded via CFHealthHub.
Modules of ‘Problem-solving’ are selected and
placed into ‘My Toolkit’ based on the barriers
identified in consultations with the
interventionist.
Participants can browse all modules of
‘Problem-solving’.
Interventionists can select modules of problem-
solving content based on the barriers identified
in consultations. Modules can be changed
throughout the intervention and these are re-
corded via CFHealthHub.
‘Talking heads’ videos are selected to match key
participant characteristics and placed into ‘My
Toolkit’. This is optional.
Participants can browse the entire ‘talking
heads’ video library.
Interventionists can select relevant videos that
match key characteristics of the participant (e.g.
age, gender, occupation, life role, problems
experienced). Videos can be changed
throughout the intervention and these are
recorded via CFHealthHub.
Goal setting and review and treatment planning
are only utilised for participants who are
motivated (want to) take more treatment.
Participants with very low motivation do not
receive these parts of the intervention. Instead
they spend more time focusing on the content
of ‘My treatment’ and relationship building with
the interventionist.
Participants can choose to set goals and make
plans at any point in a consultation or by
contacting the interventionist.
Very low motivation is determined by a
combination of a low motivation score on a
questionnaire item and discussion with the
participant in a consultation. The identification of
very low motivation is recorded where this
applies.
aWe added the following item to the BMQ-Specific questionnaire based on our qualitative work about treatment beliefs: Nebulised antibiotic treatments are more
important for my health than IV antibiotics (strongly agree to strongly disagree)
Table 8 Personalisation of the Intervention
Personalised component How personalisation is achieved
Graphs and charts show
personal data
Participants eTrack nebuliser collects and send adherence data to CFHealthHub via the Qualcomm hub for display.
Target line on graph Participants determine their adherence goal in consultation with the interventionist. This is displayed on their charts.
Plans Participants make individual plans based on discussions with the interventionist. These are made using the tools
within CFHealthHub and recorded in ‘My Toolkit’. New plans can be added and CFHealthHub records all plans for
each participant.
Home page Participants can select an image to display on their home page from a default selection, or can upload their own
image.
Notifications Participants can optionally choose to receive personalised notifications via the CFHealthHub app. These send a
message to let the participant if they have met their goal in the previous week, they have met their goal on most
days in the previous week, or an encouraging messaging to keep going if they did not.
Reminders Participants can optionally choose to receive reminders via the CFHealthHub app. These send a reminder message if
the participant has not accessed their CFHealthHub account for a period of 2 weeks.
Reward messages Reward messages are displayed on the CFHealthHub website or mobile app following log-in if the participant had
met their adherence goal for 4 out of the last 7 consecutive days. This reward is only shown if inhalation data has
been received for the last 7 consecutive days.
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(with an associated manual and training) was developed
through a rigorous and systematic development process.
It was shown to be usable and acceptable to people with
CF and the clinical community. Our development work
demonstrated that inhalation data could be automatic-
ally transferred from a third party nebuliser device and
displayed, in combination with prescription data, to pro-
vide visibility of a participant’s adherence in real-life set-
tings. Participants and clinicians were able to understand
and interpret the data display quickly and easily. The
intervention includes behaviour change techniques to
address adherence to nebuliser treatment in people with
CF, which we have been able to tailor and personalise,
so that it is appropriate for people with a range of differ-
ent barriers to adherence.
A key value of our approach is that it has incorporated
theory- and evidence-based approaches (Behaviour
Change Wheel [22, 23]) and target population-based ap-
proaches (person-based approach [24, 31]) [21]. Through-
out the development process, we have been responsive to
feedback and have changed and refined the intervention
and the way in which it is delivered. The iterative process
allowed issues to be identified quickly and updated rap-
idly, often during the early design phases, which mini-
mised the cost and resources required to make the
changes. Whilst pilot and feasibility studies are often con-
sidered to be outside of the intervention development
process [44, 54], we utilised this opportunity to make fur-
ther refinements to the intervention and its implementa-
tion in readiness for the full randomised controlled trial.
We anticipate that the refinement process will continue
following the randomised controlled trial and process
evaluation in which it is currently being tested (trial regis-
tration, ISRCTN55504164) to inform implementation in
clinical practice (trial registration, ISRCTN14464661).
Models for intervention development offer a pathway
for intervention development but not a solution. Mul-
tiple decisions have to be made along the way, and the
way in which they are made and the rationale behind
those decisions depends in part on the intervention de-
velopment team and their skills, experiences and expert-
ise. The APEASE criteria [22] informed decisions and
MoSCoW [58] enabled us to prioritise later changes, but
the information that fed into the assessment of those cri-
teria required the expertise of the development team.
Ideas that seemed practical from the perspective of a
health psychologist were not always practical from the
perspective of a computer scientist. In addition, in terms
of the likely effectiveness of the selected components,
this required reference to our conceptual framework
(see Fig. 1) and a good understanding of the theories
and principles that underpinned different aspects of it;
thus, the intervention drew on a range of different theor-
ies and evidence. The My treatment module (see Table
7) reflected the necessity-concerns framework [38], given
that knowledge and beliefs about the consequences of
treatment largely related to perceptions about the neces-
sities and concerns for nebuliser treatment and social
cognitive theory [60, 61] in terms of the role of outcome
expectancies in behaviour. Confidence building also drew
on social cognitive theory, employing a number of estab-
lished strategies to increase self-efficacy (mastery, vicari-
ous experiences, etc.). The self-monitoring, goal setting
and planning modules drew on control theory [62], to
explain how increased awareness of adherence behaviour
and the identification of a discrepancy between current
behaviour and goal might result in self-regulated behav-
iour change through action planning. Habit theory [42,
63] influenced the structure of action planning used in
the intervention, i.e. the identification of a cue or
prompt for nebuliser treatment and the use of an imple-
mentation intention [64] if cue then nebuliser treatment-
based action plan. Coping plans were used as part of
problem solving [65] in order to address the issue of cap-
ability and opportunity barriers to treatment adherence
and to help maintain adherence [43].
The development process was highly dependent on
multidisciplinary working involving a team comprised of
academics, clinicians, patients with CF, research software
engineers, and UX designers. There were varying levels
of understanding and experience of each other’s roles,
working practices, and workload. The initial model was
based on obtaining and analysing participant feedback,
agreeing design and software development requirements
followed by development sprints, giving a new release of
CFHH for each cycle of participants. However, difficul-
ties in providing qualitative feedback in a timely manner
identified previously [66] and the time required for de-
sign changes, programming, and testing meant this was
not a viable working model. Regular meetings to facili-
tate clear communication, less technical and clinical lan-
guage, and patience were required in order to develop
the intervention, and many of the desired changes re-
quired significant development time such that some of
the changes identified in stage 2 of the process were not
actually included in the CFHealthHub digital platform
until the beginning of the RCT. We recommend that fu-
ture projects have early and ongoing team discussions so
that expectations from all involved parties are realistic.
Limitations
There are some limitations of the approach. The data
that informed stages 1 and 3 of the process stemmed
from patients and clinicians from a single CF centre, and
in stage 5 (the pilot study), from a further two centres
and their associated clinical teams. This means that the
intervention was based on a relatively small sample, and
it is feasible that these centres may have differed from
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others in key ways, not least of which might have been
high levels of motivation, and the clear commitment of
the principal investigators at each site. The intervention
development process was driven by a particular develop-
ment team, made up of a particular mix of skills and ex-
pertise, and it is conceivable that a different team with
different members may have made different decisions
and arrived at a very different intervention. Whilst the
input from patients, clinicians, and the multidisciplinary
team was valuable, the process was resource and time
intensive.
The intervention that we have developed is a complex
one with multiple components tailored to meet the
needs of different patients. Whilst this is a potential
strength, it is also a potential limitation in that interven-
tion delivery is quite long, and selection of the appropri-
ate components for a particular patient relies on the
skills and training of the interventionist. An alternative
approach would have been to focus on one aspect of
need (e.g. planning and habit formation) and develop an
intervention just focused on these components. How-
ever, this would have meant that the intervention was
not suitable for patients with lower motivation. Given
that this group is of particular concern to clinicians (be-
cause they tend to be the least well), we felt that it would
not be equitable or acceptable to design an intervention
which did not target adherence increases across different
patient groups. Following the RCT, we will be able to
undertake analysis to explore which aspects of the inter-
vention produced the intended changes in process out-
comes and which did not, and if there are particular
groups of patients for whom the intervention worked
more or less well. This will enable us to pare down and
refine the intervention further so that in the future, the
intervention can be more tailored and can incorporate
just those components found to be successful in improv-
ing adherence and this will likely reduce the length and
complexity.
The initial qualitative work undertaken in stage 1 indi-
cated that for patients, nebuliser use was seen as an inte-
gral part of their CF treatment alongside chest
physiotherapy, diet, and enzymatic treatment for digest-
ive issues, and for many patients, other treatments for
co-morbid conditions including diabetes and liver condi-
tions. It was beyond the scope of this programme of
work to develop a system that could support adherence
to all of these aspects of care.
Conclusion
We have devised an intervention to increase adherence
to nebuliser treatment in adults with CF with substantial
input from patients and clinicians and which has a
strong theoretical and evidence base. The intervention
comprised a digital platform (www.cfhealthhub.com)
and components delivered in patient consultations with
an interventionist. It is usable and acceptable to people
with CF and clinicians. The intervention is currently be-
ing tested in a randomised controlled trial across 19 UK
sites.
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